Nocion, Engine among biotechs filling CMO, CSO posts
Hervolution, Contineum, Aclaris, Heron, Montai also bolster C-suite
Nocion Therapeutics Inc.’s new CMO is Matthew Frankel, who held the same title at Chemomab Therapeutics Ltd. (NASDAQ:CMMB). Waltham, Mass.-based Nocion is developing small molecule charged sodium channel blockers that selectively affect nociceptors to treat conditions involving cough, itch and pain. Its lead asset is in Phase IIb testing for refractory chronic cough.
Robert “Bob” Abraham joined Engine Biosciences Pte. Ltd. as CSO. Abraham was EVP and head of cancer biology at Odyssey Therapeutics Inc., CSO at Vividion Therapeutics Inc., and SVP and worldwide head of the oncology R&D group at Pfizer Inc. (NYSE:PFE). Engine, a Singapore and San Francisco Bay Area cancer company, is backed by Polaris Partners and ClavystBio among other investors...